An Update on Self-Amplifying mRNA Vaccine Development


Authors: A.K. Blakney, S. Ip. and A.J. Geall

Journal: Vaccines

DOI: 10.3390/vaccines9020097

Publication - Abstract

January 28, 2021

Vaccines Nucleic Acid Lipid Nanoparticles mRNA

Abstract

This review will explore the four major pillars required for design and development of an saRNA vaccine: Antigen design, vector design, non-viral delivery systems, and manufacturing (both saRNA and lipid nanoparticles (LNP)). We report on the major innovations, preclinical and clinical data reported in the last five years and will discuss future prospects.
 

limit search to this category
Advanced Search

Advanced Search

close
  • Publications
  • Application Notes
  • Posters
  • Workshops
  • Videos & Webinars
  • Articles
Search

Browse by Category

  • Application
    • Diagnostic and Imaging
    • Genetic Medicine
    • Hematology
    • Metabolic Disorders
    • Neuroscience
    • Oncology
    • Skeletal Disorders
    • Targeted Drug Delivery
    • Vaccines
    • Other Applications
    • Cell therapy
  • Formulation
    • Liposomes
    • Nucleic Acid Lipid Nanoparticles
    • Polymeric Nanoparticles
    • Other Formulations
  • Payload
    • DNA
    • microRNA
    • mRNA
    • siRNA
    • Small Molecule Drugs
    • Other Payloads


related content

Publication - Abstract

Aug 18, 2020
Nucleic Acids Research

Investigating the Pharmacodynamic Durability of GalNAc–siRNA Conjugates

C.R. Brown, S. Gupta, J. Qin, T. Racie et. al.

siRNA Nucleic Acid Lipid Nanoparticles Other Applications

In this paper Alnylam Pharmaceuticals, developer of RNAi therapeutics ONPATTRO® and GIVLAARI®, investigates the biological origins of the extended duration of N-acetylgalactosamine silencing RNA (GalNAc-siRNA) activity observed in vivo.

Read More


Publication - Abstract

Jun 13, 2018
Journal of Nucleic Acids

SERPINA1 mRNA as a Treatment for Alpha-1 Antitrypsin Deficiency

B. Connolly, C. Isaacs, L. Cheng, K.H. Asrani and R.R. Subramanian

mRNA Nucleic Acid Lipid Nanoparticles Genetic Medicine

Alpha-1-antitrypsin (AAT) deficiency is a genetic disorder that produces inactive/defective AAT due to mutations in the SERPINA1 gene encoding AAT. This disease is associated with decreased activity of AAT in the lungs and deposition of excessive defective AAT protein in the l...

Read More


Sign Up and Stay Informed
Sign up today to automatically receive new Precision NanoSystems application notes, conference posters, relevant science publications, and webinar invites.
Sign Up